Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-Month effects on coronary flow reserve and angiogenic cell mobilisation

Soon Jun Hong, Seung Cheol Choi, Jae Sang Kim, Wan Joo Shim, Seong Mi Park, Chul Min Ahn, Jae Hyung Park, Yong Hyun Kim, Do Sun Lim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To compare the effects of atorvastatin 10 mg versus 40 mg in circulating angiogenic cell mobilisations and in restoring coronary flow reserve (CFR) during the 8-month follow-up in patients with a first acute myocardial infarction (AMI). Design: CFR was measured using an intracoronary Doppler wire in 102 patients with AMI at baseline and at 8 months. Changes in the absolute number of circulating angiogenic cells were measured at baseline, 1 day, 5 days and at 8 months. Stented patients were randomly assigned to either low-dose atorvastatin 10 mg (ATOR10, n=52) or moderate-dose atorvastatin 40 mg (ATOR40, n=50). Setting: University Hospital. Results: CFR increased significantly in both groups during the 8-month follow-up. The 8-month increases from baseline in CFR were significantly greater in the ATOR40 group than in the ATOR10 group (0.99±0.69 vs 0.55±0.47, p=0.017, respectively). The serial increases in the absolute number of CD34+ and CXCR4+ cells were significantly greater in the ATOR40 group, especially at 24 h after the procedure (two-way repeated-measures analysis of variance: p=0.046 and p=0.022, respectively). Decreases from baseline for interleukin 6 (-2.94±3.31 vs -1.52±2.82 pg/ml), tumour necrosis factor α (-1.31±2.96 vs -0.01±1.29 pg/ml), soluble intercellular adhesion molecule-1 (-71±95 vs 37±83 ng/ml) and soluble vascular cell adhesion molecule-1 (-51±364 vs 190±204 ng/ml) were significantly greater in the ATOR40 group. Conclusions: The recovery of microvascular integrity after acute ischaemic injury in the ATOR40 group was expedited by greater circulating angiogenic cell mobilisations such as CD34+ and CXCR4+ cells, together with greater decreases in inflammatory cytokines and low-density lipoprotein- cholesterol concentrations. Registration number: http://ClinicalTrials.gov number, NCT00536887.

Original languageEnglish
Pages (from-to)756-764
Number of pages9
JournalHeart
Volume96
Issue number10
DOIs
Publication statusPublished - 2010 May

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-Month effects on coronary flow reserve and angiogenic cell mobilisation'. Together they form a unique fingerprint.

  • Cite this